<p>Agenus Inc.（納斯達克代碼：AGEN - 免費報告）- HC Wainwright 在 2023 年 1 月 15 日（星期四）發佈的研究報告中對 Agenus 的 2030 財年收益進行了預測。HC Wainwright 的分析師 E. Bodnar 預計該生物技術公司將在這一年每股收益為 0.34 美元。HC Wainwright 目前對該股票給予 “買入” 評級。市場普遍預計 Agenus 當前全年的每股收益為（-12.55 美元）。</p>
<p>另外，Weiss Ratings 在 2022 年 12 月 29 日（星期一）發佈的報告中重申了對 Agenus 股票的 “賣出（e+）” 評級。兩位分析師對該股票給予了買入評級，兩位給予了持有評級，還有一位對該公司的股票給予了賣出評級。根據 MarketBeat.com 的數據，該股票的平均評級為 “持有”，共識目標價為 14.50 美元。</p>
<p><strong>查看我們最新的 AGEN 股票分析</strong></p>
<h2>Agenus 股票下跌 9.2%</h2>
<p>納斯達克：AGEN 週一開盤價為 3.34 美元。該公司的市值為 1.1359 億美元，市盈率為-1.57，貝塔值為 1.58。該公司的 50 日移動平均線為 3.90 美元，200 日移動平均線為 4.42 美元。Agenus 的 52 周低點為 1.38 美元，52 周高點為 7.34 美元。</p>
<p>Agenus（納斯達克：AGEN - 獲取免費報告）最近於 2022 年 11 月 10 日發佈了其收益結果。該生物技術公司報告季度每股收益（EPS）為 1.94 美元，低於市場共識預期的 2.63 美元，差距為 0.69 美元。該公司季度收入為 3024 萬美元，而分析師預期為 8039 萬美元。</p>
<h2>Agenus 的機構交易</h2>
<p>幾家大型投資者最近增加或減少了對 AGEN 的持股。Invesco Ltd.在第一季度購買了 Agenus 的新頭寸，價值約為 88,000 美元。AQR Capital Management LLC 在第一季度將其在 Agenus 的持股增加了 3080.3%。AQR Capital Management LLC 目前擁有 441,486 股該生物技術公司的股票，價值 664,000 美元，此前在上個季度又購買了 427,604 股。Acadian Asset Management LLC 在第一季度收購了 Agenus 的新股份，價值約為 58,000 美元。Strs Ohio 在第一季度購買了 Agenus 的新股份，價值約為 214,000 美元。最後，Wealth Enhancement Advisory Services LLC 在第二季度收購了 Agenus 的新頭寸，價值約為 85,000 美元。目前 61.46% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Agenus</h2>
<p>（獲取免費報告）</p>
<p>Agenus, Inc. 納斯達克：AGEN 是一家臨牀階段的免疫腫瘤學公司，總部位於馬薩諸塞州列剋星敦。該公司專注於發現和開發旨在調節免疫系統對癌症反應的療法。Agenus 利用其在檢查點調節、疫苗技術和佐劑系統方面的專有平台，旨在提供增強抗腫瘤活性的聯合治療方案，適用於多種實體腫瘤和血液惡性腫瘤。</p>
<p>Agenus 的產品線包括針對免疫檢查點的單克隆抗體、基於細胞因子的治療藥物和基於其工程熱休克蛋白（HSP）平台的疫苗候選者。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 Agenus 更好</li>
<li>Elon 將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>用這四個簡單步驟 “防聯儲” 您的銀行賬户</li>
<li>新法律：國會批准數字美元的設立？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Agenus 嗎？</h2>
<p>在考慮 Agenus 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買...而 Agenus 並不在名單上。</p>
<p>雖然 Agenus 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

00847G804

<p>HC Wainwright 發佈了對 Agenus Inc.（NASDAQ: AGEN）2030 財年的盈利預測，預計每股收益為 0.34 美元。該公司維持 “買入” 評級，而當前全年盈利的共識預期為每股（12.55）美元。Agenus 股票目前被評為 “持有”，目標價格為 14.50 美元。該股票已下跌 9.2%，開盤價為 3.34 美元，市值為 1.1359 億美元。近期交易活動顯示該公司獲得了顯著的機構投資，專注於免疫腫瘤治療</p>

<p>Agenus Inc. (NASDAQ:AGEN - Free Report) - HC Wainwright issued their FY2030 earnings estimates for shares of Agenus in a research note issued on Thursday, January 15th. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will earn $0.34 per share for the year. HC Wainwright currently has a &#34;Buy&#34; rating on the stock. The consensus estimate for Agenus' current full-year earnings is ($12.55) per share.</p>
<div class="lb-trans"><p>Agenus Inc.（納斯達克代碼：AGEN - 免費報告）- HC Wainwright 在 2023 年 1 月 15 日（星期四）發佈的研究報告中對 Agenus 的 2030 財年收益進行了預測。HC Wainwright 的分析師 E. Bodnar 預計該生物技術公司將在這一年每股收益為 0.34 美元。HC Wainwright 目前對該股票給予 “買入” 評級。市場普遍預計 Agenus 當前全年的每股收益為（-12.55 美元）。</p>
</div><p>Separately, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Agenus in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and a consensus target price of $14.50.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 2022 年 12 月 29 日（星期一）發佈的報告中重申了對 Agenus 股票的 “賣出（e+）” 評級。兩位分析師對該股票給予了買入評級，兩位給予了持有評級，還有一位對該公司的股票給予了賣出評級。根據 MarketBeat.com 的數據，該股票的平均評級為 “持有”，共識目標價為 14.50 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on AGEN</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 AGEN 股票分析</strong></p>
</div><h2>Agenus Stock Down 9.2%</h2>
<div class="lb-trans"><h2>Agenus 股票下跌 9.2%</h2>
</div><p>NASDAQ:AGEN opened at $3.34 on Monday. The company has a market cap of $113.59 million, a P/E ratio of -1.57 and a beta of 1.58. The firm's 50 day moving average is $3.90 and its two-hundred day moving average is $4.42. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34.</p>
<div class="lb-trans"><p>納斯達克：AGEN 週一開盤價為 3.34 美元。該公司的市值為 1.1359 億美元，市盈率為-1.57，貝塔值為 1.58。該公司的 50 日移動平均線為 3.90 美元，200 日移動平均線為 4.42 美元。Agenus 的 52 周低點為 1.38 美元，52 周高點為 7.34 美元。</p>
</div><p>Agenus (NASDAQ:AGEN - Get Free Report) last released its earnings results on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.63 by ($0.69). The company had revenue of $30.24 million for the quarter, compared to analyst estimates of $80.39 million.</p>
<div class="lb-trans"><p>Agenus（納斯達克：AGEN - 獲取免費報告）最近於 2022 年 11 月 10 日發佈了其收益結果。該生物技術公司報告季度每股收益（EPS）為 1.94 美元，低於市場共識預期的 2.63 美元，差距為 0.69 美元。該公司季度收入為 3024 萬美元，而分析師預期為 8039 萬美元。</p>
</div><h2>Institutional Trading of Agenus</h2>
<div class="lb-trans"><h2>Agenus 的機構交易</h2>
</div><p>Several large investors have recently added to or reduced their stakes in AGEN. Invesco Ltd. purchased a new position in Agenus in the first quarter valued at about $88,000. AQR Capital Management LLC grew its stake in shares of Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company's stock valued at $664,000 after buying an additional 427,604 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Agenus in the first quarter valued at about $58,000. Strs Ohio purchased a new stake in shares of Agenus during the 1st quarter valued at about $214,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in Agenus during the 2nd quarter worth approximately $85,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家大型投資者最近增加或減少了對 AGEN 的持股。Invesco Ltd.在第一季度購買了 Agenus 的新頭寸，價值約為 88,000 美元。AQR Capital Management LLC 在第一季度將其在 Agenus 的持股增加了 3080.3%。AQR Capital Management LLC 目前擁有 441,486 股該生物技術公司的股票，價值 664,000 美元，此前在上個季度又購買了 427,604 股。Acadian Asset Management LLC 在第一季度收購了 Agenus 的新股份，價值約為 58,000 美元。Strs Ohio 在第一季度購買了 Agenus 的新股份，價值約為 214,000 美元。最後，Wealth Enhancement Advisory Services LLC 在第二季度收購了 Agenus 的新頭寸，價值約為 85,000 美元。目前 61.46% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Agenus</h2>
<div class="lb-trans"><h2>關於 Agenus</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Agenus, Inc NASDAQ: AGEN is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system's response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.</p>
<div class="lb-trans"><p>Agenus, Inc. 納斯達克：AGEN 是一家臨牀階段的免疫腫瘤學公司，總部位於馬薩諸塞州列剋星敦。該公司專注於發現和開發旨在調節免疫系統對癌症反應的療法。Agenus 利用其在檢查點調節、疫苗技術和佐劑系統方面的專有平台，旨在提供增強抗腫瘤活性的聯合治療方案，適用於多種實體腫瘤和血液惡性腫瘤。</p>
</div><p>Agenus' pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.</p>
<div class="lb-trans"><p>Agenus 的產品線包括針對免疫檢查點的單克隆抗體、基於細胞因子的治療藥物和基於其工程熱休克蛋白（HSP）平台的疫苗候選者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Agenus</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Agenus 更好</li>
<li>Elon 將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>用這四個簡單步驟 “防聯儲” 您的銀行賬户</li>
<li>新法律：國會批准數字美元的設立？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=AGEN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Agenus Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Agenus 嗎？</h2>
</div><p>Before you consider Agenus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Agenus 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買...而 Agenus 並不在名單上。</p>
</div><p>While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Agenus 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 發佈了 Agenus 公司 2030 財年的收益預估